0906 GMT - Novartis's positive late-stage results of its blood-disorder treatment Fabhalta bolsters confidence in reaching the drug's projected $3 billion in sales, Bryan Garnier Research analysts say in a note. The Swiss pharma company's trial showed improved hemoglobin levels in patients with paroxysmal nocturnal hemoglobinuria who switched from other therapy options. PNH is a rare and chronic blood disorder. The results should cause a muted share-price reaction as consensus estimates of Fabhalta annual sales are in line with the company's peak sales target, the analysts say. Shares fall 0.2% to 90.23 Swiss francs. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
December 06, 2024 04:07 ET (09:07 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.